Edison Investment Research - OPGEN INC (OPGN) OpGen - An increased focus on Unyvero

Report

Edison Investment Research

Sean Conroy

OpGen - An increased focus on Unyvero

OpGen Q320 sales were $1.1m, up 63% from Q319, thanks to the merger with Curetis. The company announced that it will be increasing its focus on the Unyvero platform, partly due to its level of automation and ease-of-use and partly due to the desire to improve the company’s operating efficiency. In light of this, OpGen has decided to discontinue the legacy FISH products business as of mid-2021 and also to discontinue the Acuitas AMR Gene Panel clinical trial in urine samples for complicated urinary tract infections (cUTI). The company plans to initiate a clinical trial program for cUTI with the Unyvero platform in mid-2021, expanding into invasive joint infections (IJI) in the US later in that year.

19/11/2020 5 EN

Underlying

OPGEN INC

See profile

US68373L2088 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

SmartInsider

Opgen Inc: 1 director

A director at Opgen Inc bought 25,000 shares at 0.850USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board mem...

Free Trial

January 27, 2022 January 27, 2022 1 EN

Edison Investment Research

OpGen - AMR Gene Panel clearance expected shortly

OpGen has announced that it submitted an updated 510(k) summary of its Acuitas AMR Gene Panel test in bacterial isolates to the FDA in June and believes that the review of the 510(k) clearance should be completed by the end of August (a timeline previously communicated to the company by the FDA). That said, given the ongoing pandemic, this timeline is not guaranteed. Also, OpGen continues to plan to initiate a clinical trial program for complicated urinary tract infections (cUTI) with the Unyvero platform in the coming weeks and for invasive joint infections (IJI) later in the year.

August 18, 2021 August 18, 2021 5 EN

Edison Investment Research

OpGen - AMR Gene Panel clearance expected shortly

August 18, 2021 August 18, 2021 5 EN

On the Beach Group - Feeling festive

The increase of 22% in booked total transaction value (TTV) both in H124 and for this summer, driven by successful expansion into premium and long haul and backed by its pioneering perks, confirm On the Beach’s (OTB’s) progress in addressing a market it estimates to be 5x more valuable than its core Value (3*) business (now just 25% of bookings) as well as more dynamic. Another ‘very big deal’ for OTB is its new ‘transformational’ partnership with Ryanair, its most significant low-cost carrier, ensuring free and fair access to seat supply and marking a more positive relationship, given outstan...

May 24, 2024 May 24, 2024 1 EN

Alison Turner

Alison Turner

Pan African Resources - An accounting storm in a legal teacup

This morning, Pan African announced that it may have been in technical breach of the net asset test when it paid out dividends to shareholders in the five years from FY19–23 and also when it instigated its share buyback programme in 2022. As attested to by the fact that it took five years to be noticed, the apparent breach arises from the nexus of an arcane bit of legislation and a curious distinction between the presentation currency of the group (the US dollar) and its functional currency (the South African rand) and the effect of the depreciation of the latter against the former on the dist...

May 24, 2024 May 24, 2024 1 EN

Sean Conroy

Sean Conroy

Cereno Scientific - All eyes on Q3 readout after Q1 update

Cereno Scientific’s Q124 results provided a financial update and recapped the company’s clinical plans and progress. The Phase II trial for lead asset CS1 (pulmonary arterial hypertension, PAH) remains on track for a Q324 readout and we expect the Expanded Access Program approved by the FDA in January 2024 will help Cereno build a more robust data package for the subsequent Phase IIb/III trial. Additionally, the clinical trial application (CTA) submission for CS014 to the EMA in April 2024 brings a second asset to the clinic, bolstering the company’s clinical pipeline. We believe Cereno’s liqu...

May 24, 2024 May 24, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

OpGen - An increased focus on Unyvero

Opgen Inc: 1 director

OpGen - AMR Gene Panel clearance expected shortly

OpGen - AMR Gene Panel clearance expected shortly

On the Beach Group - Feeling festive

Pan African Resources - An accounting storm in a legal teacup

Cereno Scientific - All eyes on Q3 readout after Q1 update

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe